{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:25:23Z","timestamp":1762521923389},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Multidrug resistance of bacterial pathogens has confronted physicians around the world with the threat of inefficacy of the antibiotic regime, which is particularly important for patients with sepsis. Antibiotic resistance has revived search for alternative nonantibiotic strategies. Among them, prophylaxis by vaccination is an appealing concept.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>This review provides a compact overview on available vaccines against community-acquired pathogens such as pneumococci (in synergy with influenza) and meningococci and provides an overview on the ongoing developments of vaccines targeting typical nosocomial pathogens such as <jats:italic toggle=\"yes\">Clostridium difficile<\/jats:italic>, <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>, <jats:italic toggle=\"yes\">Acintetobacter baumannii<\/jats:italic>, <jats:italic toggle=\"yes\">Klebsiella pneumonia<\/jats:italic>, and <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The effects achieved by some conjugated vaccines (e.g. against <jats:italic toggle=\"yes\">Haemophilus influenzae B<\/jats:italic> and <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>) are encouraging. Their widespread use has resulted in a decrease or almost elimination of invasive diseases by the covered pneumococcal serotypes or <jats:italic toggle=\"yes\">Haemophilus influenzae B<\/jats:italic>, respectively. These vaccines confer not only individual protection but also exploit herd protection effects. However, a multitude of failures reflects the obstacles on the way to effective and well tolerated bacterial vaccines. Regional differences in strain prevalence and variability of antigens that limit cross-protectivity remain major obstacles. However, promising candidates are in clinical development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mcc.0000000000000338","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T23:46:19Z","timestamp":1469663179000},"page":"470-476","source":"Crossref","is-referenced-by-count":18,"title":["Vaccines against major ICU pathogens: where do we stand?"],"prefix":"10.1097","volume":"22","author":[{"given":"Mathias W.","family":"Pletz","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Uebele","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"G\u00f6tz","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bekeredjian-Ding","sequence":"additional","affiliation":[{"name":"Division of Microbiology, Paul-Ehrlich-Institut, Langen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/cc7733","article-title":"The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data","volume":"13","author":"Melamed","year":"2009","journal-title":"Crit Care"},{"key":"R2-20230913","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s00134-006-0517-7","article-title":"Epidemiology of sepsis in Germany: results from a national prospective multicenter study","volume":"33","author":"Engel","year":"2007","journal-title":"Intensive Care Med"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0032-1310103","article-title":"The burden of pneumococcal pneumonia: experience of the German competence network CAPNETZ","volume":"66","author":"Pletz","year":"2012","journal-title":"Pneumologie"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1183\/09031936.00041210","article-title":"The paradox in pneumococcal serotypes: highly invasive does not mean highly lethal","volume":"36","author":"Pletz","year":"2010","journal-title":"Eur Respir J"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/infdis\/jis212","article-title":"Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells","volume":"205","author":"Clutterbuck","year":"2012","journal-title":"J Infect Dis"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.vaccine.2015.04.025","article-title":"Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults","volume":"33","author":"McFetridge","year":"2015","journal-title":"Vaccine"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1016\/j.vaccine.2015.06.078","article-title":"Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: a phase I randomized controlled study","volume":"33","author":"Brooks","year":"2015","journal-title":"Vaccine"},{"key":"R8-20230913","first-page":"w14159","article-title":"Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases","volume":"145","author":"Buhler","year":"2015","journal-title":"Swiss Med Wkly"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/339525","article-title":"Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers","volume":"185","author":"Dagan","year":"2002","journal-title":"J Infect Dis"},{"key":"R10-20230913","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1086\/504802","article-title":"Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population","volume":"43","author":"Millar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12879-015-1147-x","article-title":"Pneumococcal serotype evolution in Western Europe","volume":"15","author":"Tin Tin Htar","year":"2015","journal-title":"BMC Infect Dis"},{"key":"R12-20230913","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/inf.1980.12.issue-2.04","article-title":"The effect of polyvalent pneumococcal polysaccharide vaccine on nasopharyngeal and nasal carriage of Streptococcus pneumoniae","volume":"12","author":"Herva","year":"1980","journal-title":"Scand J Infect Dis"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1128\/CVI.00117-10","article-title":"Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster","volume":"17","author":"Russell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R14-20230913","first-page":"CD000422","article-title":"Vaccines for preventing pneumococcal infection in adults","volume":"1","author":"Moberley","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"e0146338","DOI":"10.1371\/journal.pone.0146338","article-title":"Efficacy of PPV23 in preventing pneumococcal pneumonia in adults at increased risk: a systematic review and meta-analysis","volume":"11","author":"Schiffner-Rohe","year":"2016","journal-title":"PLoS One"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(00)04237-9","article-title":"Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study","volume":"357","author":"Christenson","year":"2001","journal-title":"Lancet"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1183\/1025448x.10004913","article-title":"Pneumococcal and influenza vaccination","author":"Pletz","year":"2014","journal-title":"Community-acquired pneumonia"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of high-dose versus standard-dose influenza vaccine in older adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N Engl J Med"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.biologicals.2013.12.001","article-title":"Process development and immunogenicity studies on a serogroup \u2018X\u2019 Meningococcal polysaccharide conjugate vaccine","volume":"42","author":"Chilukuri","year":"2014","journal-title":"Biologicals"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing menigitis. Implications for vaccine development and pathogenesis","volume":"322","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40259-015-0139-0","article-title":"Bivalent rLP2086 vaccine (Trumenba(R)): a review in active immunization against invasive meningococcal group B disease in individuals aged 10\u201325 years","volume":"29","author":"Shirley","year":"2015","journal-title":"BioDrugs"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/gmic.26854","article-title":"Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance","volume":"5","author":"Gerding","year":"2014","journal-title":"Gut Microbes"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.vaccine.2016.03.028","article-title":"Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized phase 2 clinical trial","volume":"34","author":"de Bruyn","year":"2016","journal-title":"Vaccine"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.vaccine.2016.03.010","article-title":"A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults","volume":"34","author":"Sheldon","year":"2016","journal-title":"Vaccine"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","article-title":"Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers","volume":"34","author":"Bezay","year":"2016","journal-title":"Vaccine"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-1-4939-3387-7_20","article-title":"Design and purification of subunit vaccines for prevention of clostridium difficile infection","volume":"1403","author":"Karczewski","year":"2016","journal-title":"Methods Mol Biol"},{"key":"R29-20230913","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.vaccine.2014.02.026","article-title":"Development of a recombinant toxin fragment vaccine for Clostridium difficile infection","volume":"32","author":"Karczewski","year":"2014","journal-title":"Vaccine"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1016\/j.vaccine.2012.04.045","article-title":"A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models","volume":"30","author":"Tian","year":"2012","journal-title":"Vaccine"},{"key":"R31-20230913","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1128\/IAI.01950-14","article-title":"An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo","volume":"82","author":"Baliban","year":"2014","journal-title":"Infect Immun"},{"key":"R32-20230913","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4161\/hv.22434","article-title":"Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B","volume":"9","author":"Jin","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R33-20230913","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/978-1-4939-3387-7_21","article-title":"The design of a clostridium difficile carbohydrate-based vaccine","volume":"1403","author":"Monteiro","year":"2016","journal-title":"Methods Mol Biol"},{"key":"R34-20230913","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1038\/emi.2016.8","article-title":"Immunogenicity and protective efficacy of recombinant Clostridium difficile flagellar protein FliC","volume":"5","author":"Ghose","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12929-015-0171-x","article-title":"Recombinant lipoprotein-based vaccine candidates against C. difficile infections","volume":"22","author":"Huang","year":"2015","journal-title":"J Biomed Sci"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/2049-632X.12137","article-title":"Identification, immunogenicity, and cross-reactivity of type IV pilin and pilin-like proteins from Clostridium difficile","volume":"71","author":"Maldarelli","year":"2014","journal-title":"Pathog Dis"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"e81112","DOI":"10.1371\/journal.pone.0081112","article-title":"Immunization using GroEL decreases Clostridium difficile intestinal colonization","volume":"8","author":"Pechine","year":"2013","journal-title":"PLoS One"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10719-013-9489-3","article-title":"Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection","volume":"30","author":"Cox","year":"2013","journal-title":"Glycoconj J"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.chembiol.2011.03.009","article-title":"A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic","volume":"18","author":"Oberli","year":"2011","journal-title":"Chem Biol"},{"key":"R40-20230913","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.anaerobe.2015.12.001","article-title":"Immunogenicity and protective efficacy of Clostridium difficile spore proteins","volume":"37","author":"Ghose","year":"2016","journal-title":"Anaerobe"},{"key":"R41-20230913","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.vaccine.2015.02.006","article-title":"The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model","volume":"33","author":"Guo","year":"2015","journal-title":"Vaccine"},{"key":"R42-20230913","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.vaccine.2011.12.064","article-title":"Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice","volume":"30","author":"Seregin","year":"2012","journal-title":"Vaccine"},{"key":"R43-20230913","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1128\/IAI.00130-11","article-title":"Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B","volume":"79","author":"Permpoonpattana","year":"2011","journal-title":"Infect Immun"},{"key":"R44-20230913","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1128\/IAI.67.5.2145-2152.1999","article-title":"Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A","volume":"67","author":"Ward","year":"1999","journal-title":"Infect Immun"},{"key":"R45-20230913","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2013.00507","article-title":"Staphylococcus aureus colonization: modulation of host immune response and impact on human vaccine design","volume":"4","author":"Brown","year":"2014","journal-title":"Front Immunol"},{"issue":"(suppl 5)","key":"R46-20230913","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/1469-0691.12570","article-title":"Where does a Staphylococcus aureus vaccine stand?","volume":"20","author":"Fowler","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R47-20230913","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrmicro3308","article-title":"Models matter: the search for an effective Staphylococcus aureus vaccine","volume":"12","author":"Salgado-Pabon","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"R48-20230913","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.vaccine.2016.03.110","article-title":"Status of vaccine research and development of vaccines for Staphylococcus aureus","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"issue":"(suppl 1)","key":"R49-20230913","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.ijantimicag.2008.06.009","article-title":"Vaccination and passive immunisation against Staphylococcus aureus","volume":"32","author":"Schaffer","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R50-20230913","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.4161\/hv.21872","article-title":"Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors","volume":"8","author":"Anderson","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R51-20230913","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcimb.2012.00016","article-title":"Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials","volume":"2","author":"Bagnoli","year":"2012","journal-title":"Front Cell Infect Microbiol"},{"key":"R52-20230913","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/cid\/cis033","article-title":"Challenges for a universal Staphylococcus aureus vaccine","volume":"54","author":"Proctor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R53-20230913","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4161\/hv.34414","article-title":"Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study","volume":"11","author":"Fattom","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R54-20230913","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2013.3010","article-title":"Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial","volume":"309","author":"Fowler","year":"2013","journal-title":"JAMA"},{"key":"R55-20230913","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2015.02.024","article-title":"A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults","volume":"33","author":"Nissen","year":"2015","journal-title":"Vaccine"},{"key":"R56-20230913","doi-asserted-by":"crossref","first-page":"e0116945","DOI":"10.1371\/journal.pone.0116945","article-title":"Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease","volume":"10","author":"Rozemeijer","year":"2015","journal-title":"PLoS One"},{"key":"R57-20230913","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/21645515.2015.1011021","article-title":"Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial","volume":"11","author":"Levy","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"R58-20230913","doi-asserted-by":"crossref","first-page":"e0147767","DOI":"10.1371\/journal.pone.0147767","article-title":"One dose of Staphylococcus aureus 4C-Staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T Cells, and IL-17A","volume":"11","author":"Mancini","year":"2016","journal-title":"PLoS One"},{"key":"R59-20230913","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/iub.534","article-title":"Acinetobacter infection: an emerging threat to human health","volume":"63","author":"Visca","year":"2011","journal-title":"IUBMB Life"},{"key":"R60-20230913","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.micpath.2016.04.019","article-title":"Mucosal immunization with purified OmpA elicited protective immunity against infections caused by multidrug-resistant Acinetobacter baumannii","volume":"96","author":"Zhang","year":"2016","journal-title":"Microb Pathog"},{"key":"R61-20230913","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fmicb.2016.00158","article-title":"Immunoprotective efficacy of acinetobacter baumannii outer membrane protein, filf, predicted in silico as a potential vaccine candidate","volume":"7","author":"Singh","year":"2016","journal-title":"Front Microbiol"},{"key":"R62-20230913","doi-asserted-by":"crossref","first-page":"20724","DOI":"10.1038\/srep20724","article-title":"Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii","volume":"6","author":"Huang","year":"2016","journal-title":"Sci Rep"},{"key":"R63-20230913","doi-asserted-by":"crossref","first-page":"e77631","DOI":"10.1371\/journal.pone.0077631","article-title":"Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii","volume":"8","author":"Moriel","year":"2013","journal-title":"PLoS One"},{"key":"R64-20230913","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/IAI.05653-11","article-title":"Poly-N-acetyl-beta-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections","volume":"80","author":"Bentancor","year":"2012","journal-title":"Infect Immun"},{"key":"R65-20230913","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.molimm.2015.07.031","article-title":"Immunological evaluation of OMV(PagL)+Bap(1-487aa) and AbOmpA(8-346aa)+Bap(1-487aa) as vaccine candidates against Acinetobacter baumannii sepsis infection","volume":"67","author":"Badmasti","year":"2015","journal-title":"Mol Immunol"},{"key":"R66-20230913","doi-asserted-by":"crossref","first-page":"e100727","DOI":"10.1371\/journal.pone.0100727","article-title":"Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"R67-20230913","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1016\/j.vaccine.2011.06.001","article-title":"Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii","volume":"29","author":"McConnell","year":"2011","journal-title":"Vaccine"},{"key":"R68-20230913","doi-asserted-by":"crossref","first-page":"22332","DOI":"10.1038\/srep22332","article-title":"An inactivated antibiotic-exposed whole-cell vaccine enhances bactericidal activities against multidrug-resistant Acinetobacter baumannii","volume":"6","author":"Shu","year":"2016","journal-title":"Sci Rep"},{"key":"R69-20230913","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.vaccine.2014.02.083","article-title":"Intranasal immunization protects against Acinetobacter baumannii-associated pneumonia in mice","volume":"33","author":"KuoLee","year":"2015","journal-title":"Vaccine"},{"key":"R70-20230913","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.tim.2014.09.003","article-title":"Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding","volume":"22","author":"Chen","year":"2014","journal-title":"Trends Microbiol"},{"key":"R71-20230913","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1086\/675598","article-title":"Frequency of Klebsiella pneumoniae carbapenemase (KPC)-producing and non-KPC-producing Klebsiella species contamination of healthcare workers and the environment","volume":"35","author":"Rock","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R72-20230913","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/clinids\/23.1.179","article-title":"Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma","volume":"23","author":"Campbell","year":"1996","journal-title":"Clin Infect Dis"},{"key":"R73-20230913","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/JCM.44.1.102-107.2006","article-title":"Seroepidemiology of Klebsiella pneumoniae in an Australian Tertiary Hospital and its implications for vaccine development","volume":"44","author":"Jenney","year":"2006","journal-title":"J Clin Microbiol"},{"key":"R74-20230913","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.immuni.2011.10.018","article-title":"Th17 cells mediate clade-specific, serotype-independent mucosal immunity","volume":"35","author":"Chen","year":"2011","journal-title":"Immunity"},{"key":"R75-20230913","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.coi.2013.03.011","article-title":"Th17 cell based vaccines in mucosal immunity","volume":"25","author":"Kumar","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"R76-20230913","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4161\/hv.23225","article-title":"Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae","volume":"9","author":"Lundberg","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"R77-20230913","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/CVI.00275-10","article-title":"Protective efficacy of DNA vaccines encoding outer membrane protein A and OmpK36 of Klebsiella pneumoniae in mice","volume":"18","author":"Kurupati","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R78-20230913","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1038\/emm.2015.59","article-title":"Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity","volume":"47","author":"Lee","year":"2015","journal-title":"Exp Mol Med"},{"key":"R79-20230913","first-page":"35","article-title":"Immunovac-VP-4 for prevention of acute respiratory diseases in children's communities","author":"Egorova","year":"2010","journal-title":"Zh Mikrobiol Epidemiol Immunobiol"},{"key":"R80-20230913","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.26565","article-title":"A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF\/I vaccine (IC43) in healthy volunteers","volume":"10","author":"Westritschnig","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R81-20230913","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.vaccine.2009.10.080","article-title":"Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers","volume":"28","author":"Bumann","year":"2010","journal-title":"Vaccine"},{"key":"R82-20230913","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1465-9921-8-57","article-title":"Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I\/II study","volume":"8","author":"Baumann","year":"2007","journal-title":"Respir Res"},{"key":"R83-20230913","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0264-410X(00)00235-8","article-title":"Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients","volume":"19","author":"Kim","year":"2000","journal-title":"Vaccine"},{"key":"R84-20230913","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.0702403104","article-title":"A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients","volume":"104","author":"Doring","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R85-20230913","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/IAI.74.2.968-974.2006","article-title":"Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects","volume":"74","author":"Cripps","year":"2006","journal-title":"Infect Immun"},{"key":"R86-20230913","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2014.00012","article-title":"Designing vaccines for the twenty-first century society","volume":"5","author":"Finco","year":"2014","journal-title":"Front Immunol"},{"key":"R87-20230913","doi-asserted-by":"crossref","first-page":"e83449","DOI":"10.1371\/journal.pone.0083449","article-title":"A phase I clinical study of a live attenuated Bordetella pertussis vaccine \u2013 BPZE1: a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers","volume":"9","author":"Thorstensson","year":"2014","journal-title":"PLoS One"}],"container-title":["Current Opinion in Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00075198-201610000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:06:49Z","timestamp":1694632009000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00075198-201610000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mcc.0000000000000338","relation":{},"ISSN":["1070-5295","1531-7072"],"issn-type":[{"value":"1070-5295","type":"print"},{"value":"1531-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}